Opus Genetics, Inc. (IRD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 3.92 |
| Open | 3.95 |
| Day High | 3.98 |
| Day Low | 3.8 |
| 52-Week High | 5.81 |
| 52-Week Low | 0.9 |
| Volume | 755,093 |
| Average Volume | 806,358 |
| Market Cap | 322.01M |
| PE | -2.98 |
| EPS | -1.31 |
| Moving Average 50 Days | 4.79 |
| Moving Average 200 Days | 3.13 |
| Change | -0.02 |
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
GlobeNewswire Inc.
Mar 10, 2026 11:00 AM GMT
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in p
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
GlobeNewswire Inc.
Feb 27, 2026 3:10 PM GMT
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and thre